World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 111 5293 4968 2860 2651 809 50873

Mark J. Ratain publications per year

The chart shows the history of publications by Mark J. Ratain between 1985 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Mark J. Ratain published across 41 years, from 1985 to 2025, averaging 23.2 papers a year. Output peaked at 139 publications in 2023. 28 of the 952 publications appeared in the last two years.

No. of publications
25 50 75 100 125
Bar chart. Horizontal axis: year, 1985 to 2025. Vertical axis: number of publications, 0 to 139. Peak 139 publications in 2023. 1985: 4 publications 1986: 7 publications 1987: 11 publications 1988: 10 publications 1989: 9 publications 1990: 7 publications 1991: 14 publications 1992: 11 publications 1993: 14 publications 1994: 13 publications 1995: 11 publications 1996: 19 publications 1997: 17 publications 1998: 18 publications 1999: 13 publications 2000: 12 publications 2001: 17 publications 2002: 24 publications 2003: 22 publications 2004: 42 publications 2005: 30 publications 2006: 34 publications 2007: 41 publications 2008: 30 publications 2009: 27 publications 2010: 28 publications 2011: 27 publications 2012: 27 publications 2013: 31 publications 2014: 33 publications 2015: 22 publications 2016: 17 publications 2017: 20 publications 2018: 22 publications 2019: 27 publications 2020: 28 publications 2021: 32 publications 2022: 14 publications 2023: 139 publications 2024: 11 publications 2025: 17 publications
1985 2025

952 publications in total across all disciplines

View publications per year as a table
Mark J. Ratain: publications per year, 1985 to 2025
Year Publications
1985 4
1986 7
1987 11
1988 10
1989 9
1990 7
1991 14
1992 11
1993 14
1994 13
1995 11
1996 19
1997 17
1998 18
1999 13
2000 12
2001 17
2002 24
2003 22
2004 42
2005 30
2006 34
2007 41
2008 30
2009 27
2010 28
2011 27
2012 27
2013 31
2014 33
2015 22
2016 17
2017 20
2018 22
2019 27
2020 28
2021 32
2022 14
2023 139
2024 11
2025 17
Total 952
Download as CSV

Mark J. Ratain publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mark J. Ratain sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 801–820 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 809 publications — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204 809
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Mark J. Ratain D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mark J. Ratain sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 110–111 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 111 D-Index — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429 111
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Mark J. Ratain is affiliated with the University of Chicago in the United States. Their research focuses primarily within the field of Medicine, with particular emphasis on Oncology, Economics and Econometrics, Pharmacology, Molecular Biology, and Pulmonary and Respiratory Medicine.

The scientist's work covers a range of topics including Health Systems, Economic Evaluations, Quality of Life; Pharmacogenetics and Drug Metabolism; Colorectal Cancer Treatments and Studies; Economic and Financial Impacts of Cancer; Statistical Methods in Clinical Trials; Cancer Genomics and Diagnostics; and Chronic Lymphocytic Leukemia Research.

Frequent publication venues for their research include:

  • UNC Libraries
  • Clinical Pharmacology & Therapeutics
  • Journal of Clinical Oncology
  • The Journal of Clinical Pharmacology
  • JAMA Oncology

Recent papers authored or co-authored by Mark J. Ratain encompass a variety of clinical and pharmacological themes, such as:

  • "COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia" (2020, Clinical Pharmacology & Therapeutics)
  • "Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value" (2020, Clinical Pharmacology & Therapeutics)
  • "Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments" (2021, Journal of Clinical Oncology)
  • "Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19" (2020, JAMA Oncology)
  • "Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy" (2020, Clinical Pharmacology & Therapeutics)

Co-authors frequently collaborating with Mark J. Ratain include:

  • Garth W. Strohbehn
  • Kouros Owzar
  • Peter H. O'Donnell
  • Keith Danahey
  • Daniel A. Goldstein

The scientist has also been recognized as a member of the Association of American Physicians.

Best Publications

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

    Mark J. Ratain;Tim Eisen;Walter M. Stadler;Keith T. Flaherty

  • Tumour heterogeneity in the clinic

    Philippe L. Bedard;Aaron R. Hansen;Aaron R. Hansen;Mark J. Ratain;Lillian L. Siu;Lillian L. Siu

  • Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

    Federico Innocenti;Samir D. Undevia;Lalitha Iyer;Pei Xian Chen

  • Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.

    Lalitha Iyer;Christopher D. King;Peter F. Whitington;Mitchell D. Green

  • UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

    L Iyer;S Das;L Janisch;M Wen

  • Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

    T Eisen;T Ahmad;K T Flaherty;M Gore

  • Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)

    Jonas A. de Souza;Bonnie J. Yap;Kristen Wroblewski;Victoria Blinder

  • Perceptions of cancer patients and their physicians involved in phase I trials.

    Christopher Daugherty;Mark J. Ratain;Eugene Grochowski;Carol Stocking

  • Metabolic Fate of Irinotecan in Humans: Correlation of Glucuronidation with Diarrhea

    Elora Gupta;Timothy M. Lestingi;Rosemarie Mick;Jacqueline Ramirez

  • Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

    Razelle Kurzrock;Steven I. Sherman;Douglas W. Ball;Arlene A. Forastiere

  • The development of a financial toxicity patient-reported outcome in cancer: The COST measure.

    Jonas A. de Souza;Bonnie J. Yap;Fay J. Hlubocky;Kristen Wroblewski

  • Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

    Jason J. Luke;Jeffrey M. Lemons;Theodore G. Karrison;Sean P. Pitroda

  • Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism

    Lalitha Iyer;Diana Hall;Soma Das;Melissa A. Mortell

  • Oral chemotherapy: rationale and future directions.

    Mark D. DeMario;Mark J. Ratain

  • Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung.

    MJ Ratain;LS Kaminer;JD Bitran;RA Larson

  • Pharmacokinetic variability of anticancer agents

    Samir D. Undevia;Gonzalo Gomez-Abuin;Mark J. Ratain

  • Pharmacogenomics: Challenges and Opportunities

    Dan M. Roden;Russ B. Altman;Neal L. Benowitz;David A. Flockhart

  • Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients.

    H M Golomb;A Jacobs;A Fefer;H Ozer

  • The Development of a Financial Toxicity Patient-Reported Outcome in Cancer

    Jonas A. de Souza;Bonnie J. Yap;Fay J. Hlubocky;Kristen Wroblewski

Frequent Co-Authors

Richard L. Schilsky
Richard L. Schilsky University of Chicago
Federico Innocenti
Federico Innocenti University of North Carolina at Chapel Hill
Everett E. Vokes
Everett E. Vokes University of Chicago
Theodore Karrison
Theodore Karrison University of Chicago
Walter M. Stadler
Walter M. Stadler University of Chicago
Nicholas J. Vogelzang
Nicholas J. Vogelzang University of Nevada Reno
Gini F. Fleming
Gini F. Fleming University of Chicago
Rosemarie Mick
Rosemarie Mick University of Pennsylvania
Soma Das
Soma Das University of Chicago
Harvey M. Golomb
Harvey M. Golomb University of Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine can open doors to a variety of related healthcare fields. For those seeking flexibility and affordability, online programs are an excellent option. Many students start their journey with nursing, exploring what is the cheapest online college for nursing? to help minimize debt while gaining essential qualifications.

As you progress, you may look at advancing your career by becoming a nurse practitioner. Today’s affordable online FNP programs allow working professionals to upskill from home, preparing for more specialized, in-demand roles.

Many registered nurses choose to further their education through the cheapest RN to BSN programs, which expand career options and earning potential. For those passionate about academic research or leadership, online PhD nursing programs offer a pathway to the highest levels in healthcare education and practice.

Exploring these online pathways can help you build a rewarding medical career, tailored to your interests, ambitions, and budget.

Best Scientists Citing Mark J. Ratain

Trending Scientists

Recently Published Articles